Grafapex (Treosulfan)

Treosulfan is a chemotherapy medicine given to prepare the body for a stem cell transplant in people with acute myeloid leukemia or myelodysplastic syndrome. It is given as an infusion into a vein, together with another medicine called fludarabine. It works by damaging the DNA of blood-forming cells so the new donor cells can take their place.

Brand names:Grafapex
Medication

What people taking Grafapex (Treosulfan) report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Grafapex (Treosulfan)

What It's For

Treosulfan, sold in the US as Grafapex, is a chemotherapy medicine used to prepare the body for an allogeneic stem cell transplant, in which a person receives blood-forming stem cells from a donor. It is approved for adults and children 1 year and older who have acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, or myelodysplastic syndrome (MDS), a group of disorders in which the bone marrow makes faulty blood cells. It is always given together with fludarabine, another chemotherapy medicine. This combination is called a conditioning or preparative regimen: a short, intensive course of treatment given in the days just before the donor cells are infused. Treosulfan is not used on its own and is not a treatment people take outside a transplant program. Grafapex was approved in the US in 2025 as an alternative to conditioning based on busulfan, an older chemotherapy medicine used for the same purpose. In the main study, adults aged 18 to 70 who were 50 or older or had other significant health problems received either treosulfan or a lower-intensity busulfan schedule, each with fludarabine. People in the treosulfan group had a lower risk of dying during follow-up. Approval for children rests on that adult study plus dosing and safety data from 111 children and teenagers.

How It Works

Treosulfan belongs to a group of chemotherapy medicines called alkylating agents. In the body it changes into active forms that attach to DNA and damage it, so cells that are dividing quickly can no longer copy themselves and die. Before a donor transplant, that effect does two jobs. It clears out the person's own bone marrow, including leukemia or abnormal MDS cells that may remain, which makes room for the donor stem cells. It also suppresses the immune system so it is less likely to reject the incoming cells. Fludarabine adds to the immune suppression. The donor cells then settle in the marrow and gradually start producing new blood cells.

Dosage & Administration

Treosulfan is given only in a hospital transplant unit, as an infusion into a vein that runs over about two hours. It is given once a day for three days, on the fourth, third and second days before the transplant. Fludarabine is given daily for five days, starting six days before the transplant. The dose of treosulfan is calculated from body surface area, an estimate based on height and weight. The team gives anti-nausea medicine before the first dose and keeps it going on a fixed schedule through the three days. Because the regimen wipes out the bone marrow, it is not started unless donor cells are ready. The dose is also kept at the approved level: in an earlier study, a higher dose led to more early deaths and serious reactions. The nurse checks the IV line before each infusion. If redness, swelling or pain develops where the line enters the skin, say so right away, because treosulfan that leaks out of the vein can damage the surrounding tissue.

Side Effects

Very low blood counts are expected in everyone who receives treosulfan, because clearing the marrow is the point of the treatment. Until the donor cells start working, the body has few white blood cells to fight infection, few red cells to carry oxygen and few platelets to stop bleeding. Transfusions and medicines to prevent or treat infection are a routine part of this period. Infections can be serious and may need antibiotic, antiviral or antifungal treatment in hospital. Fever, a new cough, headache, diarrhea or any other new or worsening sign of infection should be reported to the transplant team immediately. In the main adult study, the most common other side effects in the month after transplant were muscle and bone pain, mouth sores, fever, nausea, swelling, vomiting, rash, diarrhea and headache. Liver blood tests often rise. Children had liver and digestive side effects more often than adults. Treosulfan can irritate the skin, especially in sweaty areas and under dressings, and it passes into the urine. On infusion days it helps to keep the skin clean and dry, wash the armpits, groin and other skin folds with plain water, skip creams and wear loose clothing. For children in diapers, change them often for 12 hours after each infusion. Less often, treosulfan can cause seizures. The team watches for them and may give a preventive medicine to people at higher risk, including infants. In the main study, about 2 in 100 adults died of lung complications related to the regimen within 30 days of transplant.

Interactions & Warnings

Treosulfan carries an FDA boxed warning, the agency's most prominent kind of warning, about severe and long-lasting loss of blood cell production. Without a stem cell transplant to replace the marrow, this would be life-threatening, which is why treosulfan is given only as part of a planned transplant and blood counts are checked daily until the new marrow recovers. Like other alkylating chemotherapy, treosulfan raises the risk of developing a second, different cancer later in life. The risk is higher in people with Fanconi anemia or other inherited conditions that weaken the body's ability to repair DNA, and its safety in those groups has not been established. Treosulfan can harm a developing baby. People who can become pregnant need a pregnancy test within a week before starting and should use effective birth control during treatment and for 6 months after the last dose. Men with a partner who could become pregnant should use effective birth control during treatment and for 3 months afterward. Tell the team right away about a known or suspected pregnancy. Breastfeeding should stop during treatment and for 1 week after the last dose. Treosulfan can also cause temporary or permanent infertility in both women and men. Treosulfan slows two liver enzymes that break down many other medicines, so it can raise the levels of some of them. The transplant team reviews every medicine and adjusts doses where small changes matter. The only absolute reason not to use it is an allergy to the medicine.

What to Expect

Treosulfan is a short course within a much longer transplant process. The three infusions take place in hospital, followed a couple of days later by the infusion of donor cells. After that comes a waiting period while blood counts are at their lowest. In the main adult study, infection-fighting white cells recovered a median of 18 days after the transplant, though this ranged from about one to six weeks. During this time people usually stay in or near the transplant center, with daily blood tests, transfusions as needed and close watch for infection, mouth soreness and other side effects. Once the donor cells are producing blood cells reliably, the focus shifts to recovery from the transplant itself, which brings its own medicines, risks and follow-up visits that continue for months or years. Treosulfan is not taken again after the conditioning days, but some of its effects, such as possible infertility and the small long-term risk of a second cancer, remain part of long-term follow-up.

Questions to Ask Your Doctor

  1. 1.Why are you recommending treosulfan rather than busulfan or another conditioning regimen for me or my child?
  2. 2.How long will blood counts likely stay low, and what will we do to prevent and watch for infection during that time?
  3. 3.Is there any option to preserve fertility before conditioning starts, and how much time do we have to decide?
  4. 4.Which of my current medicines need to be stopped or adjusted while I receive treosulfan?
  5. 5.What long-term follow-up will I need for late effects such as a second cancer?

Last reviewed • Oct 2026

Educational content, not medical advice.